Preclinical and phase I/II study findings on VEGF165 gene therapy reported at ESC congress Sep. 5, 2001
MMP-1-sparing matrix metalloproteinase inhibitors possessing antiangiogenic/antitumor properties Sep. 5, 2001
RSS